Pyridone-based EZH2 inhibitor anticancer candidates: synthetic approaches, comparative analysis, and future perspectives
Future Medicinal Chemistry · 2026-04-18 · 18 (8) · 993-1006
DOI: 10.1080/17568919.2026.2636498 ↗At a glance
Übersichtsarbeit in Future Medicinal Chemistry, published online on 2026-02-24. Written by Hamada S Abulkhair. Institution: Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Egypt. Major MEDLINE topics: Pyridones, Antineoplastic Agents, Enhancer of Zeste Homolog 2 Protein. Cited 1 times so far (Crossref); 84 references. The full text is freely available in PubMed Central.
Abstract (original language)
Intet abstract tilgængeligt.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Egypt.
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Horus University-Egypt, New Damietta, Egypt.
ORCID profiles: Hamada S Abulkhair
Cite
APA
Abulkhair, H. S. (2026). Pyridone-based EZH2 inhibitor anticancer candidates: synthetic approaches, comparative analysis, and future perspectives. Future Medicinal Chemistry, 18(8), 993-1006. https://doi.org/10.1080/17568919.2026.2636498
Vancouver
Abulkhair HS. Pyridone-based EZH2 inhibitor anticancer candidates: synthetic approaches, comparative analysis, and future perspectives. Future Medicinal Chemistry. 2026;18(8):993-1006. doi:10.1080/17568919.2026.2636498
BibTeX
@article{Abulkhair2026,
author = {Abulkhair, Hamada S},
title = {Pyridone-based EZH2 inhibitor anticancer candidates: synthetic approaches, comparative analysis, and future perspectives},
journal = {Future Medicinal Chemistry},
year = {2026},
volume = {18},
number = {8},
pages = {993--1006},
doi = {10.1080/17568919.2026.2636498}
}
EUVIMED